A "Classic" Ketogenic Diet as a Complementary Therapeutic Management on Patients With High-grade Gliomas and Brain Metastases.

Trial ID: NCT05564949

Interventional - Phase Unknown - Recruiting

The survival interval of patients with gliomas ranges between 12 to 15 months. Recent findings revealed that dietary interventions to reduce glucose and glycolytic pathways could have a therapeutic effect. Ketosis can be an effective therapy to extend the survival of patients with gliomas.

Conditions

• Brain
• Cancer

Interventions

• CKD

Eligibility

Inclusion criteria

• Age 18-80
• Karnofsky Performance Score of 50 or more.
• Newly diagnosed, histologically confirmed glioblastoma grade 4, or secondary metastases or progression after surgical resection, radiation and chemotherapy.
• Normal function of liver and kidneys
• Ability to sign informed consent form

Exclusion criteria

• Diabetes mellitus
• Life expectancy \>3 months
• Inability to adhere to diet
• Inability to give informed consent form
• Cholecystectomy last 1 year (before the study entry)
• Diagnosis of genetic disorder of fat metabolism

Sponsor

Attikon Hospital

Source: ClinicalTrials.gov

Search more clinical trials on myTomorrows